Covid-19: Greek medicine will be tested in severe patients in our country

For the first time, a Greek drug will be tested in hospitals of our country in patients treated with COVID-19 and who have Acute Respiratory Distress Syndrome (ARDS). The reason for the innovative experimental drug AMY-101 that targets the central protein of supplement C3 and which is a “child” of the Greek pharmaceutical company “Amyntas”. In six Greek hospitals The founder of “Amyntas” Giannis Lambris exclusively at VIMA-Science the founder of “Amyntas”, Professor of Immunology at the University of Pennsylvania Mr. Giannis Lambris, will probably start even this week in six hospitals: the University Hospital of Alexandroupolis, AHEPA and “Papanikolaou” Thessaloniki, the University Hospital of Larissa, the University Hospital of Ioannina and the “Evangelismos” hospital in Athens. This is a randomized clinical trial in which 62 patients with ARDS syndrome but who have not reached the last step of the “ladder” will participate. as well as the corresponding number of patients in the control group. The aim of the test will be to demonstrate whether AMY-101 administration can save these individuals from intubation and death. Test design Based on the design, treatment will be given intravenously over two weeks in combination conventional treatment received by hospitalized patients. The follow-up of the patients will last 44 days in total in order to record the course of their health. If all goes well in this first phase, the test will be opened to include more patients. US and German approvals The approval by the National Medicines Agency (EOF) for the AMY-101 test in Greece comes after similar approvals who has already received the drug from both the US Food and Drug Administration (FDA) and the German Federal Institute for Drugs and Medical Devices (BfArM). It is noted that a trial of treatment for inpatients in Italy in the context of palliative use is already underway with extremely encouraging results. According to them, the treatment seemed to offer a rapid remission of the hyperinflammatory reaction associated with COVID-19 and to “give breath” to patients who eventually stop needing oxygen. The supplement and the key role of The AMY- 101 is a third-generation inhibitor that targets the supplement, a key mechanism of the body’s natural immunity, and in particular a central complement protein, C3. C3 has been shown to be largely responsible for initiating the inflammatory response and the increased secretion of cytokines by immune system cells (macrophages and monocytes). Given that a number of data have recently shown the catalytic role that uncontrolled activation of the supplement plays in the immune response – this is the so-called “cytokine storm” – and the thrombotic complications associated with the occurrence of severe COVID-19, it is proven that the supplement and the treatments related to it can be a very attractive approach to reduce inflammatory tissue damage in COVID-19 disease. Encouraging first results Commenting on the start of drug testing in our country, Mr. Lambris told BIMA-Science that “It is the first time that an original Greek drug enters a clinical trial process in Greek hospitals for the treatment of ARDS syndrome in hospitalized patients. The approval of the AEO comes after the respective important approvals of extremely strict organizations such as the FDA and BfArM. We hope to have good results so that the treatment is approved and can be available on a larger scale for the benefit of many patients. “All the evidence so far gives us optimism as AMY-101 has shown in recent trials in Italy that it can significantly help COVID-19 ARDS patients to avoid intubation and death.” we will inform you about the latest. Because any treatment that promises to offer relief and life to more and more patients struggling with the extremely “difficult”, as it turns out every day, viral “enemy” called SARS-CoV-2, is welcome. One more reason if this treatment is also “blue and white”, with all that this may imply – apart from the first thing that is the salvation of patients – for our country. Follow it on Google News and be the first to know all the newsSee all the latest News from Greece and the World, at

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *